Literature DB >> 30413483

β-Catenin-RAS interaction serves as a molecular switch for RAS degradation via GSK3β.

Sang-Kyu Lee1,2, Woo-Jeong Jeong1,2, Yong-Hee Cho1,2, Pu-Hyeon Cha1,2, Jeong-Su Yoon1,2, Eun Ji Ro1,2, Sooho Choi1,3, Jeong-Min Oh1,3, Yunseok Heo1,3, Hyuntae Kim1,2, Do Sik Min1,4, Gyoonhee Han1,2, Weontae Lee1,3, Kang-Yell Choi5,2.   

Abstract

RAS proteins play critical roles in various cellular processes, including growth and transformation. RAS proteins are subjected to protein stability regulation via the Wnt/β-catenin pathway, and glycogen synthase kinase 3 beta (GSK3β) is a key player for the phosphorylation-dependent RAS degradation through proteasomes. GSK3β-mediated RAS degradation does not occur in cells that express a nondegradable mutant (MT) β-catenin. Here, we show that β-catenin directly interacts with RAS at the α-interface region that contains the GSK3β phosphorylation sites, threonine 144 and threonine 148 residues. Exposure of these sites by prior β-catenin degradation is required for RAS degradation. The introduction of a peptide that blocks the β-catenin-RAS interaction by binding to β-catenin rescues the GSK3β-mediated RAS degradation in colorectal cancer (CRC) cells that express MT β-catenin. The coregulation of β-catenin and RAS stabilities by the modulation of their interaction provides a mechanism for Wnt/β-catenin and RAS-ERK pathway cross-talk and the synergistic transformation of CRC by both APC and KRAS mutations.
© 2018 The Authors.

Entities:  

Keywords:  GSK3β phosphorylation of RAS; colorectal cancer; regulation of RAS stability; α‐Interface region of RAS; β‐Catenin‐RAS interaction

Mesh:

Substances:

Year:  2018        PMID: 30413483      PMCID: PMC6280641          DOI: 10.15252/embr.201846060

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  28 in total

1.  NMRPipe: a multidimensional spectral processing system based on UNIX pipes.

Authors:  F Delaglio; S Grzesiek; G W Vuister; G Zhu; J Pfeifer; A Bax
Journal:  J Biomol NMR       Date:  1995-11       Impact factor: 2.835

2.  Ras stabilization through aberrant activation of Wnt/β-catenin signaling promotes intestinal tumorigenesis.

Authors:  Woo-Jeong Jeong; Juyong Yoon; Jong-Chan Park; Soung-Hoon Lee; Seung-Hoon Lee; Saluja Kaduwal; Hoguen Kim; Jong-Bok Yoon; Kang-Yell Choi
Journal:  Sci Signal       Date:  2012-04-10       Impact factor: 8.192

Review 3.  The APC gene in colorectal cancer.

Authors:  R Fodde
Journal:  Eur J Cancer       Date:  2002-05       Impact factor: 9.162

Review 4.  Mechanisms of RAS/β-catenin interactions.

Authors:  Eva Zeller; Katharina Hammer; Melissa Kirschnick; Albert Braeuning
Journal:  Arch Toxicol       Date:  2013-03-13       Impact factor: 5.153

5.  Signaling aptamer/protein binding by a molecular light switch complex.

Authors:  Yaxin Jiang; Xiaohong Fang; Chunli Bai
Journal:  Anal Chem       Date:  2004-09-01       Impact factor: 6.986

6.  Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.

Authors:  Byoung-San Moon; Woo-Jeong Jeong; Jieun Park; Tae Il Kim; Do Sik Min; Kang-Yell Choi
Journal:  J Natl Cancer Inst       Date:  2014-02       Impact factor: 13.506

7.  Small-molecule binding of the axin RGS domain promotes β-catenin and Ras degradation.

Authors:  Pu-Hyeon Cha; Yong-Hee Cho; Sang-Kyu Lee; JaeHeon Lee; Woo-Jeong Jeong; Byoung-San Moon; Ji-Hye Yun; Jee Sun Yang; Sooho Choi; Juyong Yoon; Hyun-Yi Kim; Mi-Yeon Kim; Saluja Kaduwal; Weontae Lee; Do Sik Min; Hoguen Kim; Gyoonhee Han; Kang-Yell Choi
Journal:  Nat Chem Biol       Date:  2016-06-13       Impact factor: 15.040

8.  Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation.

Authors:  Timothy A Chan; Zhenghe Wang; Long H Dang; Bert Vogelstein; Kenneth W Kinzler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

9.  Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo.

Authors:  Owen J Sansom; Valerie Meniel; Julie A Wilkins; Alicia M Cole; Karin A Oien; Victoria Marsh; Thomas J Jamieson; Carmen Guerra; Gabrielle H Ashton; Mariano Barbacid; Alan R Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-07       Impact factor: 11.205

10.  PINE-SPARKY: graphical interface for evaluating automated probabilistic peak assignments in protein NMR spectroscopy.

Authors:  Woonghee Lee; William M Westler; Arash Bahrami; Hamid R Eghbalnia; John L Markley
Journal:  Bioinformatics       Date:  2009-06-03       Impact factor: 6.937

View more
  15 in total

1.  LZTR1 facilitates polyubiquitination and degradation of RAS-GTPases.

Authors:  Taiki Abe; Ikumi Umeki; Shin-Ichiro Kanno; Shin-Ichi Inoue; Tetsuya Niihori; Yoko Aoki
Journal:  Cell Death Differ       Date:  2019-07-23       Impact factor: 15.828

2.  WDR76 degrades RAS and suppresses cancer stem cell activation in colorectal cancer.

Authors:  Eun Ji Ro; Yong-Hee Cho; Woo-Jeong Jeong; Jong-Chan Park; Do Sik Min; Kang-Yell Choi
Journal:  Cell Commun Signal       Date:  2019-07-30       Impact factor: 5.712

3.  WDR76 mediates obesity and hepatic steatosis via HRas destabilization.

Authors:  Jong-Chan Park; Woo-Jeong Jeong; Seol Hwa Seo; Kang-Yell Choi
Journal:  Sci Rep       Date:  2019-12-23       Impact factor: 4.379

Review 4.  K-Ras prenylation as a potential anticancer target.

Authors:  Marcell Baranyi; László Buday; Balázs Hegedűs
Journal:  Cancer Metastasis Rev       Date:  2020-12       Impact factor: 9.264

Review 5.  ETMR: a tumor entity in its infancy.

Authors:  Sander Lambo; Katja von Hoff; Andrey Korshunov; Stefan M Pfister; Marcel Kool
Journal:  Acta Neuropathol       Date:  2020-06-29       Impact factor: 17.088

Review 6.  The Ins and Outs of RAS Effector Complexes.

Authors:  Christina Kiel; David Matallanas; Walter Kolch
Journal:  Biomolecules       Date:  2021-02-07

Review 7.  Targeting BRAF and RAS in Colorectal Cancer.

Authors:  Helene Bellio; Jean David Fumet; Francois Ghiringhelli
Journal:  Cancers (Basel)       Date:  2021-05-03       Impact factor: 6.639

8.  KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

Authors:  David S Hong; Marwan G Fakih; John H Strickler; Jayesh Desai; Gregory A Durm; Geoffrey I Shapiro; Gerald S Falchook; Timothy J Price; Adrian Sacher; Crystal S Denlinger; Yung-Jue Bang; Grace K Dy; John C Krauss; Yasutoshi Kuboki; James C Kuo; Andrew L Coveler; Keunchil Park; Tae Won Kim; Fabrice Barlesi; Pamela N Munster; Suresh S Ramalingam; Timothy F Burns; Funda Meric-Bernstam; Haby Henary; Jude Ngang; Gataree Ngarmchamnanrith; June Kim; Brett E Houk; Jude Canon; J Russell Lipford; Gregory Friberg; Piro Lito; Ramaswamy Govindan; Bob T Li
Journal:  N Engl J Med       Date:  2020-09-20       Impact factor: 176.079

9.  Small molecule-induced simultaneous destabilization of β-catenin and RAS is an effective molecular strategy to suppress stemness of colorectal cancer cells.

Authors:  Yong-Hee Cho; Eun Ji Ro; Jeong-Su Yoon; Dong-Kyu Kwak; Jaebeom Cho; Dong Woo Kang; Ho-Young Lee; Kang-Yell Choi
Journal:  Cell Commun Signal       Date:  2020-03-06       Impact factor: 5.712

Review 10.  Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology.

Authors:  Loretta László; Anita Kurilla; Tamás Takács; Gyöngyi Kudlik; Kitti Koprivanacz; László Buday; Virag Vas
Journal:  Cells       Date:  2021-03-17       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.